2025-09-28 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the provided data, presented in English with key numbers first, followed by more detailed analysis.

## JNJ Stock Analysis

**Review Ticker:** JNJ (Johnson & Johnson)

**Company Overview:** Johnson & Johnson is a global healthcare company engaged in the research, development, manufacture, and sale of a broad range of products in the healthcare field.

### 1. Relative Performance Analysis

*   **JNJ Cumulative Return:** 36.60%
*   **VOO (S&P 500) Cumulative Return:** 66.41%
*   **Absolute Divergence:** -29.81%
*   **Relative Divergence:** 35.8

**Analysis:** JNJ has significantly underperformed the S&P 500 (VOO) over the period examined. The relative divergence indicates that JNJ's underperformance is positioned towards the lower end of its historical range compared to VOO. The current divergence from VOO is -31.9%.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha  | Beta  | Cap(B) |
|------------|--------|--------|--------|-------|--------|
| 2015-2017  | 26.0%  | 66.8%  | 17.0%  | -0.1 | 336.5  |
| 2016-2018  | 11.0%  | 56.3%  | 12.0%  | -0.1 | 310.8  |
| 2017-2019  | 17.0%  | 71.6%  | 13.0%  | 0.0 | 351.3  |
| 2018-2020  | 16.0%  | 79.3%  | -9.0%  | 0.1  | 379.0  |
| 2019-2021  | 39.0%  | 79.3%  | 11.0%  | 0.3  | 412.0  |
| 2020-2022  | 14.0%  | 79.7%  | 0.0%   | 0.2  | 425.4  |
| 2021-2023  | -14.0% | 79.7%  | -31.0% | 0.2  | 377.5  |
| 2022-2024  | -39.0% | 79.7%  | -51.0% | 0.2  | 348.3  |
| 2023-2025  | 5.0%   | 79.6%  | -30.0% | 0.1  | 432.8  |

**Analysis:**

*   **CAGR:** Fluctuates significantly across different periods, showing inconsistent growth.
*   **MDD:** High Maximum Drawdown values suggest significant volatility and potential for large losses.
*   **Alpha:**  Generally positive in earlier periods but turns negative in recent years, indicating underperformance relative to its benchmark. The most recent period (2023-2025) shows a significant negative alpha.
*   **Beta:**  Low Beta values (close to 0) suggest that JNJ's price movements are not strongly correlated with the overall market.
*   **Cap:** Market capitalization shows an increase over time but has recently decreased, reflecting market value fluctuations.

### 2. Recent Price Action

*   **Current Price:** 179.71
*   **Previous Close:** 177.73
*   **Change:** 1.11 (A positive change indicating a recent price increase.)
*   **5-Day Moving Average:** 176.95
*   **20-Day Moving Average:** 177.15
*   **60-Day Moving Average:** 171.42

**Analysis:** The current price is above all three moving averages (5, 20, and 60-day), suggesting a short-term upward trend. The recent jump in price (change of 1.11 from the previous close) reinforces this short-term bullish signal.

### 3. Market Risk Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 53.88 (Neutral - neither overbought nor oversold)
*   **PPO:** -0.09 (Slightly below zero, suggesting a possible weakening trend.)
*   **Hybrid Signal:** Cash 67% - Sell 4.1% of holdings (14 shares - Caution - MRI: 0.60)
*   **Recent (20-day) Relative Divergence Change:** -1.6 (Indicates a recent decline in relative performance compared to the benchmark)
*   **Expected Return:** -29.5% (Significant underperformance vs. S&P 500 projected over a long-term investment horizon)

**Analysis:**

*   The MRI suggests a high level of general market safety, but the Hybrid Signal recommends a high cash position and a partial sell-off, indicating caution specifically for JNJ.  This discrepancy suggests that while the overall market might be favorable, JNJ faces specific headwinds.
*   The negative expected return indicates that, based on current conditions, JNJ is projected to underperform the S&P 500 significantly over a long-term investment horizon.
*   The recent price jump is not enough to offset the more cautious overall indicators.

### 4. Recent News & Significant Events

*   **[2025-09-27]** JNJ to Withdraw the LINC Reflux Management System from Markets Outside the U.S. (Potentially negative, depending on the financial impact.)
*   **[2025-09-26]** JNJ Surpasses Market Returns: Some Facts Worth Knowing (Potentially positive, but needs to be evaluated in context of longer-term underperformance.)
*   **[2025-09-26]** AbbVie Successfully Navigated Top-line Growth Post Humira LOE? (Indirectly relevant as a competitor analysis.)
*   **[2025-09-26]** Trump's new tariffs on pharma, furniture, & trucks: What to know (Potentially negative for the pharmaceutical industry in general, creating uncertainty.)
*   **[2025-09-26]** Big pharma stocks rise as Street reacts to latest presidential tariff plan (Contradictory to the previous bullet point - could indicate short-term market reaction is different from long-term implications.)
*   **[2025-09-26]** Jim Cramer Discusses Kenvue Inc. (KVUE) & Legal Issues (Potentially relevant as Kenvue was spun off from JNJ; legal issues could still impact JNJ.)

**Analysis:** The news is mixed. The withdrawal of the LINC system and potential tariff impacts are concerns. The article claiming JNJ surpasses market returns needs careful examination to understand the timeframe and context. The news regarding Kenvue is relevant due to the recent spin-off.

### 4-2) Analyst Opinions

*   **Consensus:** Buy (Mean: 2.17)
*   **Target Price:** 179.64 (Average), 206.00 (High), 155.00 (Low)

**Analysis:**  Analysts have a generally positive outlook (Buy rating) with an average target price around the current price. However, the wide range between the high and low target prices suggests significant uncertainty about the stock's future performance. The lack of recent rating changes data doesn't provide insights into the evolving sentiment of analysts.

### 5. Recent Earnings Analysis

| Date       | EPS  | Revenue     |
|------------|------|-------------|
| 2025-07-24 | 2.3  | 23.74 B$    |
| 2025-04-23 | 4.57 | 21.89 B$    |
| 2024-10-23 | 1.12 | 22.47 B$    |
| 2024-07-25 | 1.95 | 22.45 B$    |
| 2025-07-24 | 1.95 | 22.45 B$    |

**Analysis:**  Earnings per share (EPS) and revenue figures show volatility. It's important to investigate *why* the EPS fluctuates so significantly. It may be due to one-time charges, accounting changes, or other factors that don't necessarily reflect the underlying business performance. The repetition of 2025-07-24 data point needs clarification.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue     | Profit Margin |
|------------|-------------|---------------|
| 2025-06-30 | $23.74B    | 67.87%        |
| 2025-03-31 | $21.89B    | 66.40%        |
| 2024-12-31 | $22.52B    | 68.35%        |
| 2024-09-30 | $22.47B    | 69.01%        |
| 2024-06-30 | $22.45B    | 69.40%        |

**Capital and Profitability:**

| Quarter    | Equity      | ROE      |
|------------|-------------|----------|
| 2025-06-30 | $78.47B    | 7.06%   |
| 2025-03-31 | $78.11B    | 14.08%  |
| 2024-12-31 | $71.49B    | 4.80%   |
| 2024-09-30 | $70.16B    | 3.84%   |
| 2024-06-30 | $71.54B    | 6.55%   |

**Analysis:**

*   **Revenue:** Shows some fluctuation, with the latest quarter (2025-06-30) being the highest.
*   **Profit Margin:** Remains consistently high, indicating strong pricing power and efficient cost management. The profit margins remain high, showing JNJ is maintaining strong profitability.
*   **Equity:** Generally increasing, suggesting growth in the company's net worth.
*   **ROE:**  Highly variable, suggesting inconsistency in generating profit from shareholder equity. The fluctuation in ROE highlights potential variability in how effectively JNJ is deploying its equity to generate profits.

### 7. Comprehensive Analysis

**Summary:**

Based on the provided data, JNJ presents a mixed investment picture.

*   **Underperformance:** The most significant concern is JNJ's substantial underperformance relative to the S&P 500. The negative expected return reinforces this concern.
*   **Mixed Signals:** Technical indicators offer conflicting signals. The price is above its moving averages, suggesting a short-term uptrend, while the Hybrid Signal advocates for a cautious approach.
*   **High Risk for investment:** The MRI suggests a High level of general market safety.
*   **Financial Health:** JNJ maintains strong financial health with consistently high profit margins. However, ROE is fluctuating.
*   **Mixed News:** Recent news events present both potential challenges (product withdrawal, tariff risks) and opportunities.
*   **Analyst Sentiment:** Analysts have a positive (buy) rating but target prices vary widely.

**Overall Recommendation:**

While JNJ exhibits financial strength, the underperformance relative to the S&P 500 and the negative expected return warrant caution. Further investigation is needed to determine the root causes of the underperformance and whether management has a credible plan to address them.

**Before investing, consider the following:**

*   **Dig deeper into the reasons for JNJ's underperformance:**  What specific factors are contributing to this?
*   **Assess the impact of the product withdrawal and potential tariffs:**  How significantly will these events impact JNJ's financials?
*   **Analyze the details of the "JNJ Surpasses Market Returns" article:** What timeframe does it cover, and what metrics are used?
*   **Monitor Kenvue's performance and legal situation:** How might Kenvue's issues impact JNJ?
*   **Understand the drivers behind EPS volatility:** What caused the significant changes in EPS over the analyzed periods?
*   **Evaluate the reasons behind ROE fluctuations:** What factors are causing the variability in JNJ's efficiency in generating profit from shareholder equity?
